Adolore BioTherapeutics Secures U.S. Patent for CA8* Gene Therapy in Chronic Pain Treatment

Adolore BioTherapeutics, based in Delray Beach, Florida, has received U.S. Patent No. 11,911,450 for its CA8* gene therapy technology aimed at treating chronic pain. This technology utilizes a sophisticated rdHSV-CA8* vector, a replication-deficient disease-free HSV variant, that was developed for chronic osteoarthritis (OA) knee pain treatment, signaling a significant move towards addressing the urgent need for opioid-free pain management alternatives.

The patented gene therapies are based on carbonic anhydrase-8-like (CA8*) analgesic peptides, indicating a new approach to treating chronic pain without the need for oral opioids, which pose risks of dependence, abuse, and severe side effects. Adolore's therapies target nociceptive, neuropathic, and inflammatory pain across a broad spectrum of conditions, offering potential without the systemic exposure issues linked to previous Kv7 channel activators.

Dr. Roy Levitt, Inventor and Adolore's Founder/Chairman, highlighted the therapy's promise in delivering targeted, localized treatment while minimizing biodistribution to unaffected tissues. The technology derives from a license agreement with the University of Miami, introducing a novel treatment pathway for conditions like erythromelalgia and OA-induced chronic knee pain, areas with few existing safe and efficacious treatments.

The announcement of this patent aligns with Adolore's progression towards clinical testing, supported by a UG3/UH3 NIH/NINDS HEAL program grant for pre-clinical development of its pain management solutions. These developments come at a critical time, given the widespread need for alternative pain treatments amidst the ongoing opioid crisis.